Results 91 to 100 of about 117,976 (202)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes

Revista Mexicana de Endocrinología, Metabolismo y Nutrición
Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretins ...
Graciela Zambrano-Galván, Ángel González-Romero, Miguel A. Reyes-Romero, Abelardo Camacho-Luis   +3 more
doaj   +1 more source

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]

, 2019
Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada, Iwasaki, Mari, Kaunitz, Jonathan D   +2 more
core  

Ülseratif kolitli hastalarda `glucagon like peptide-1` ve `glucagon like peptide-2` düzeyleri

, 2020
Giriş-Amaç: Ülseratif kolit hastalığı barsağın kronik inflamatuvar bir hastalığıdır. ?Glucagon like peptide-1? barsak enteroendokrin L hücrelerinden salgılanan ve kan şekerinin düzenlenmesinde görevli bir peptiddir. ?Glucagon like peptide-2? de barsak enteroendokrin L hücrelerinden salgılanır ve barsak mukoza bütünlüğünün korunmasında görevlidir ...
openaire   +1 more source

Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis

Frontiers in Pharmacology
Bone is a highly dynamic organ that changes with the daily circadian rhythm. During the day, bone resorption is suppressed due to eating, while it increases at night. This circadian rhythm of the skeleton is regulated by gut hormones.
Hongyu Liu, Hongyu Liu, Huimin Xiao, Huimin Xiao, Sufen Lin, Sufen Lin, Huan Zhou, Huan Zhou, Yizhao Cheng, Yizhao Cheng, Baocheng Xie, Baocheng Xie, Daohua Xu, Daohua Xu   +13 more
doaj   +1 more source

Use of Glucagon-like peptide 2 (GLP-2) analogs in inflammatory bowel disease

Quality in Sport
Introduction: Inflammatory bowel disease (IBD) is a chronic condition that involves long-term treatment and chronic idiopathic inflammation within the gastrointestinal tract.
Dobromiła Osuch, Piotr Zatyka, Adam Słomczyński, Agata Pawłowska, Michal Rabenda, Piotr Janik, Dominika Opala   +6 more
doaj   +1 more source

Computational Design of Potent and Selective d-Peptide Agonists of the Glucagon-like Peptide-2 Receptor. [PDF]

J Med Chem, 2023
Valiente PA, Nim S, Kim J, Kim PM.
europepmc   +1 more source

Euglycemic Ketoacidosis After the Addition of Glucagon-Like Peptide-1 Receptor Agonist: A Case Report

Annals of Internal Medicine: Clinical Cases
Euglycemic diabetic ketoacidosis (euDKA) is an acute, life-threatening metabolic emergency. It has been associated with several factors, including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Ernest Oji Kanu, Daniel K. Kim, Rejeesh Menon, Carissa Burke, Nathan Vicknair   +4 more
doaj   +1 more source

Plasma glucagon-like peptide-2 concentrations are lower in dogs with chronic enteropathies than in healthy dogs. [PDF]

Am J Vet Res, 2023
Riehm MD, Mayhue EJ, Jugan MC.
europepmc   +1 more source

Evidence review : liraglutide for the treatment of type 2 diabetes [PDF]

, 2011
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National Institute
Cummins, E. (Ewen), HASH(0x5574f4171138), Royle, Pamela, Shyangdan, D. (Deepson), Waugh, Norman   +4 more
core  

Potential determinants of low circulating glucagon-like peptide 2 concentrations in Zambian children with non-responsive stunting. [PDF]

Exp Physiol, 2023
Besa E, Tembo MJ, Mulenga C, Mweetwa M, Choudhry N, Chandwe K, Storer C, Head R, Amadi B, Haritunians T, McGovern D, Kwenda G, Peiris M, Kelly P.   +13 more
europepmc   +1 more source